Literature DB >> 20575033

Analysis of von Willebrand factor structure by multimer analysis.

Marlies R Ledford-Kraemer1.   

Abstract

Analysis of von Willebrand factor (VWF) structure is achieved by performing a highly specialized procedure, VWF multimer analysis. The test is reserved for the reference or specialized laboratory environment. The assay is qualitative (though under some circumstances multimers may be quantified) in that it assesses the overall size distribution of VWF multimers as well as their individual internal structure. The test is used predominantly to type or subtype von Willebrand disease. The analysis of VWF multimers generally consists of four steps: (1) electrophoresis of plasma in an agarose gel, (2) either gel fixation or transfer of the electrophoretic protein product to a membrane, (3) immunodetection of the protein, and (4) evaluation of the protein in the gel or membrane. The assay is complex, time consuming, requires specialized equipment and technical expertise, and is not standardized. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20575033     DOI: 10.1002/ajh.21739

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syndrome, and gastrointestinal bleeding.

Authors:  Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

2.  Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution.

Authors:  Inge Vangenechten; Alain Gadisseur
Journal:  Res Pract Thromb Haemost       Date:  2020-07-16

3.  Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use.

Authors:  Marika Pikta; Timea Szanto; Margus Viigimaa; Sandra Lejniece; Dārta Balode; Kadri Saks; Valdas Banys
Journal:  J Med Biochem       Date:  2021-03-12       Impact factor: 3.402

4.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

5.  Von Willebrand disease type 2M: Correlation between genotype and phenotype.

Authors:  Dominique P M S M Maas; Ferdows Atiq; Nicole M A Blijlevens; Paul P T Brons; Sandy Krouwel; Britta A P Laros-van Gorkom; Frank W G Leebeek; Laurens Nieuwenhuizen; Selene C M Schoormans; Annet Simons; Daniëlle Meijer; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2021-11-21       Impact factor: 16.036

6.  Plasma Level of von Willebrand Factor Propeptide at Diagnosis: A Marker of Subsequent Renal Dysfunction in Autoimmune Rheumatic Diseases.

Authors:  Noritaka Yada; Kiyomi Yoshimoto; Hiromasa Kawashima; Ryo Yoneima; Nobushiro Nishimura; Yoshiaki Tai; Emiko Tsushima; Makiko Miyamoto; Shiro Ono; Masanori Matsumoto; Takashi Fujimoto; Kenji Nishio
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

7.  Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers.

Authors:  Annette E Bowyer; Karen J Goodfellow; Holger Seidel; Philipp Westhofen; Francesca Stufano; Anne Goodeve; Stephen Kitchen; Michael Makris
Journal:  Res Pract Thromb Haemost       Date:  2018-08-12

8.  Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Authors:  Johan Boender; Ferdows Atiq; Marjon H Cnossen; Johanna G van der Bom; Karin Fijnvandraat; Joke de Meris; Moniek P M de Maat; Karin P M van Galen; Britta A P Laros-van Gorkom; Karina Meijer; Jeroen Eikenboom; Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.